KQB198 + dasatinib

KQB198 + dasatinib is an investigational **combination therapy** for advanced hematologic malignancies, specifically evaluated in adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase who have relapsed after or are intolerant to at least two tyrosine kinase inhibitors. KQB198 is under clinical investigation, and its specific mechanism of action is not fully disclosed publicly. Dasatinib is a well-established oral small molecule tyrosine kinase inhibitor approved for Ph+ CML and Ph+ acute lymphoblastic leukemia (ALL). It targets multiple kinases, including BCR-ABL, SRC family kinases, c-KIT, EPHA2, and PDGFRβ, thereby inhibiting growth and proliferation of leukemic cells[2][3][7]. The combination is in phase 1/1b clinical trials to evaluate its safety, tolerability, pharmacokinetics, and anti-tumor activity, with Kumquat Biosciences as the lead sponsor[1][3][7].

Other names

BMS-354825BMS354825BMS 354825